Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2020-11-09 Investor Presentation
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find enclosed the Investors Presentation (Q2' FY21) November, 2020, based on the financial performance of the Company for the quarter ended 30th September, 2020.
Investor Presentation Classification · 100% confidence The document is titled 'Investors Presentation (Q2' FY21) November, 2020' and is addressed to stock exchanges. It contains detailed financial performance data for the quarter ended 30th September 2020, including profit after tax, segment-wise revenue, product portfolio, manufacturing facilities, and growth highlights. The content is structured as a presentation with charts, graphs, and business strategy information. There is no indication that this is a full annual or interim report, audit report, or earnings release summary. Instead, it is a detailed presentation aimed at investors, focusing on financials, strategy, and market position for the quarter. Therefore, the document fits the definition of an Investor Presentation (IP). The document length (over 10,000 characters) and detailed content confirm it is the presentation itself, not just an announcement or summary.
2020-11-09 English
Financial Result Updates
Regulatory Filings
2020-11-09 English
The Board of Directors of the Company, in their meeting held on Monday, 9th November, 2020, have, inter-alia, considered and approved the Un-audited Standalone and Consolidated Financial ....
Interim / Quarterly Report Classification · 95% confidence The document is dated 09/11/2020 and is addressed to BSE Limited, indicating a regulatory filing to a stock exchange. It announces the outcome of a Board of Directors meeting held on the same date, where the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2020 were considered and approved. The document includes detailed financial tables with revenue, expenditure, profit, and other financial metrics for the quarter and half year periods, as well as notes on the review by the Audit Committee and statutory auditors. The presence of unaudited financial results for a quarter and half year period, along with a limited review report, aligns with the characteristics of an Interim / Quarterly Report. The document is substantive and contains actual financial data and analysis, not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2020-11-09 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement from Morepen Laboratories Limited dated November 9, 2020, reporting the outcome of a Board of Directors meeting. It includes unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2020, pursuant to SEBI regulations. The document contains detailed financial tables with revenue, expenses, profit, and assets and liabilities statements. It also mentions a limited review report by statutory auditors. The presence of comprehensive financial data for a quarterly period, including profit and loss and balance sheet information, indicates this is a financial report for a period shorter than a full fiscal year. The document is not merely an announcement of a report but contains substantive financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2021
2020-11-09 English
Please find attached Outcome of Board Meeting held on 09.11.2020
Interim / Quarterly Report Classification · 95% confidence The document is dated 09/11/2020 and is addressed to BSE Limited, indicating a regulatory filing to a stock exchange. It announces the outcome of a Board of Directors meeting held on 9th November 2020, where the unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2020 were considered and approved. The document includes detailed financial tables with revenue, expenditure, profit before tax, tax expense, net profit, and other comprehensive income for the quarter and half year periods. It also mentions a limited review report by statutory auditors, which is typical for interim or quarterly financial results. The presence of actual financial data and analysis for a period shorter than a full fiscal year (quarter and half year) confirms this is a comprehensive interim/quarterly report rather than just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2020-11-09 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (National Stock Exchange of India Ltd. and BSE Limited) regarding the loss of share certificates by shareholders and the request for issuance of duplicate share certificates. It references Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to reporting loss of share certificates. The content is about notifying the exchange of lost share certificates and does not contain financial data, earnings, management changes, or other report types. It is an official regulatory announcement related to share certificates but not a financial report or management disclosure. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length is under 5,000 characters and is a direct notification, not a report publication announcement or a financial report.
2020-11-07 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.